P3 Health Partners (PIII) Competitors

$4.03 +0.46 (+12.89%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$5.48 +1.45 (+35.86%)

As of 04:37 AM Eastern

PIII vs. PARK, XGN, SERA, DCGO, and EUDA

Should you buy P3 Health Partners stock or one of its competitors? MarketBeat compares P3 Health Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with P3 Health Partners include Park Dental Partners (PARK), Exagen (XGN), Sera Prognostics (SERA), DocGo (DCGO), and EUDA Health (EUDA). These companies are all part of the "healthcare" industry.

How does P3 Health Partners compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

7.8% of P3 Health Partners shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by company insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -10.14%. Park Dental Partners' return on equity of 0.00% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
P3 Health Partners	-10.14%	-302.33%	-20.72%

Park Dental Partners has higher earnings, but lower revenue than P3 Health Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.33	N/A	N/A	N/A
P3 Health Partners	$1.46B	0.02	-$147.95M	-$45.20	N/A

Park Dental Partners presently has a consensus target price of $21.75, indicating a potential upside of 20.97%. P3 Health Partners has a consensus target price of $3.50, indicating a potential downside of 13.15%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts plainly believe Park Dental Partners is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Park Dental Partners had 3 more articles in the media than P3 Health Partners. MarketBeat recorded 7 mentions for Park Dental Partners and 4 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.93 beat Park Dental Partners' score of 0.81 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Park Dental Partners	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Park Dental Partners beats P3 Health Partners on 8 of the 13 factors compared between the two stocks.

How does P3 Health Partners compare to Exagen?

Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 12.6% of Exagen shares are owned by insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

P3 Health Partners has a net margin of -10.14% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
P3 Health Partners	-10.14%	-302.33%	-20.72%

Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$68.38M	1.36	-$19.95M	-$0.89	N/A
P3 Health Partners	$1.46B	0.02	-$147.95M	-$45.20	N/A

Exagen presently has a consensus target price of $9.25, suggesting a potential upside of 140.26%. P3 Health Partners has a consensus target price of $3.50, suggesting a potential downside of 13.15%. Given Exagen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Exagen is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Exagen has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

In the previous week, Exagen had 8 more articles in the media than P3 Health Partners. MarketBeat recorded 12 mentions for Exagen and 4 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.93 beat Exagen's score of 0.47 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exagen beats P3 Health Partners on 10 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, P3 Health Partners had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 4 mentions for P3 Health Partners and 3 mentions for Sera Prognostics. P3 Health Partners' average media sentiment score of 0.93 beat Sera Prognostics' score of 0.63 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sera Prognostics has higher earnings, but lower revenue than P3 Health Partners. Sera Prognostics is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	876.21	-$31.93M	-$0.65	N/A
P3 Health Partners	$1.46B	0.02	-$147.95M	-$45.20	N/A

P3 Health Partners has a net margin of -10.14% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
P3 Health Partners	-10.14%	-302.33%	-20.72%

Sera Prognostics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Sera Prognostics currently has a consensus target price of $5.00, suggesting a potential upside of 179.33%. P3 Health Partners has a consensus target price of $3.50, suggesting a potential downside of 13.15%. Given Sera Prognostics' stronger consensus rating and higher possible upside, research analysts clearly believe Sera Prognostics is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sera Prognostics beats P3 Health Partners on 9 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to DocGo?

DocGo (NASDAQ:DCGO) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

P3 Health Partners has higher revenue and earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.18	-$182.40M	-$1.91	N/A
P3 Health Partners	$1.46B	0.02	-$147.95M	-$45.20	N/A

P3 Health Partners has a net margin of -10.14% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
P3 Health Partners	-10.14%	-302.33%	-20.72%

56.4% of DocGo shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 3.8% of DocGo shares are owned by insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DocGo currently has a consensus target price of $2.38, suggesting a potential upside of 301.79%. P3 Health Partners has a consensus target price of $3.50, suggesting a potential downside of 13.15%. Given DocGo's stronger consensus rating and higher possible upside, research analysts clearly believe DocGo is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, DocGo had 11 more articles in the media than P3 Health Partners. MarketBeat recorded 15 mentions for DocGo and 4 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.93 beat DocGo's score of -0.08 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DocGo has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Summary

DocGo beats P3 Health Partners on 9 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to EUDA Health?

P3 Health Partners (NASDAQ:PIII) and EUDA Health (NASDAQ:EUDA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

EUDA Health has lower revenue, but higher earnings than P3 Health Partners. EUDA Health is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.02	-$147.95M	-$45.20	N/A
EUDA Health	$6.82M	5.34	-$2.77M	-$2.40	N/A

EUDA Health has a net margin of 0.00% compared to P3 Health Partners' net margin of -10.14%. EUDA Health's return on equity of 0.00% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-10.14%	-302.33%	-20.72%
EUDA Health	N/A	N/A	N/A

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 4.4% of EUDA Health shares are held by institutional investors. 17.8% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

P3 Health Partners currently has a consensus target price of $3.50, suggesting a potential downside of 13.15%. EUDA Health has a consensus target price of $55.00, suggesting a potential upside of 280.36%. Given EUDA Health's higher probable upside, analysts plainly believe EUDA Health is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
EUDA Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, P3 Health Partners had 2 more articles in the media than EUDA Health. MarketBeat recorded 4 mentions for P3 Health Partners and 2 mentions for EUDA Health. P3 Health Partners' average media sentiment score of 0.93 beat EUDA Health's score of 0.44 indicating that P3 Health Partners is being referred to more favorably in the media.

Company	Overall Sentiment
P3 Health Partners	Positive
EUDA Health	Neutral

P3 Health Partners has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, EUDA Health has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Summary

EUDA Health beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PIII vs. The Competition

Export

Metric	P3 Health Partners	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.75M	$1.41B	$6.34B	$12.37B
Dividend Yield	N/A	N/A	2.80%	5.35%
P/E Ratio	-0.09	64.07	20.66	25.63
Price / Sales	0.02	6.18	545.73	76.59
Price / Cash	N/A	22.91	43.26	56.33
Price / Book	-0.19	5.23	9.94	6.97
Net Income	-$147.95M	-$54.76M	$3.55B	$333.62M
7 Day Performance	13.52%	-2.61%	1.70%	1.09%
1 Month Performance	65.16%	2.91%	0.49%	3.08%
1 Year Performance	-51.45%	-4.83%	39.38%	35.68%

P3 Health Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PIII P3 Health Partners	1.0808 of 5 stars	$4.03 +12.9%	$3.50 -13.2%	-50.7%	$25.75M	$1.46B	N/A	500	News Coverage Gap Up High Trading Volume
PARK Park Dental Partners	3.1416 of 5 stars	$17.60 -0.5%	$21.75 +23.6%	N/A	$79.87M	$244.49M	N/A	1,208	Earnings Report Analyst Upgrade
XGN Exagen	4.1325 of 5 stars	$3.09 -0.3%	$9.38 +203.4%	-33.8%	$74.84M	$66.57M	N/A	220	Earnings Report Analyst Forecast
SERA Sera Prognostics	2.7225 of 5 stars	$1.88 -1.1%	$5.00 +166.0%	-20.4%	$74.37M	$80K	N/A	120
DCGO DocGo	2.9836 of 5 stars	$0.68 +1.0%	$2.38 +247.3%	-57.8%	$66.85M	$322.20M	N/A	3,568	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PIII) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

P3 Health Partners (PIII) Competitors

PIII vs. PARK, XGN, SERA, DCGO, and EUDA

How does P3 Health Partners compare to Park Dental Partners?

Summary

How does P3 Health Partners compare to Exagen?

Summary

How does P3 Health Partners compare to Sera Prognostics?

Summary

How does P3 Health Partners compare to DocGo?

Summary

How does P3 Health Partners compare to EUDA Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

P3 Health Partners (PIII) Competitors

PIII vs. PARK, XGN, SERA, DCGO, and EUDA

How does P3 Health Partners compare to Park Dental Partners?

Do insiders & institutionals have more ownership in PARK or PIII?

Is PARK or PIII more profitable?

Which has higher earnings and valuation, PARK or PIII?

Do analysts rate PARK or PIII?

Does the media prefer PARK or PIII?

Summary

How does P3 Health Partners compare to Exagen?

Do institutionals & insiders have more ownership in XGN or PIII?

Is XGN or PIII more profitable?

Which has stronger earnings & valuation, XGN or PIII?

Do analysts rate XGN or PIII?

Which has more volatility and risk, XGN or PIII?

Does the media favor XGN or PIII?

Summary

How does P3 Health Partners compare to Sera Prognostics?

Does the media refer more to SERA or PIII?

Do insiders and institutionals have more ownership in SERA or PIII?

Which has higher valuation and earnings, SERA or PIII?

Is SERA or PIII more profitable?

Which has more risk and volatility, SERA or PIII?

Do analysts recommend SERA or PIII?

Summary

How does P3 Health Partners compare to DocGo?

Which has higher valuation and earnings, DCGO or PIII?

Is DCGO or PIII more profitable?

Do insiders and institutionals have more ownership in DCGO or PIII?

Do analysts recommend DCGO or PIII?

Does the media refer more to DCGO or PIII?

Which has more risk and volatility, DCGO or PIII?

Summary

How does P3 Health Partners compare to EUDA Health?

Which has better valuation and earnings, PIII or EUDA?

Is PIII or EUDA more profitable?

Do institutionals and insiders have more ownership in PIII or EUDA?

Do analysts rate PIII or EUDA?

Does the media prefer PIII or EUDA?

Which has more volatility and risk, PIII or EUDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools